Mitsubishi Tanabe to buy Israel's NeuroDerm for $1.1 bn

July 24, 2017

Japan's Mitsubishi Tanabe Pharma announced Monday a billion-dollar deal to buy an Israeli company that specialises in developing treatments for Parkinson's disease.

The Osaka-based firm said it will acquire all of Nasdaq-listed NeuroDerm's outstanding shares for $1.1 billion at a price of $39 per share.

The deal is subject to approval by NeuroDerm shareholders as well as regulatory approval.

NeuroDerm develops treatments for patients suffering from Parkinson's disease, as well as other disorders related to the central nervous system.

The company, which has been supported by grants from the Michael J Fox Foundation for Parkinson's Research, aims to radically change the way the disease is treated through reformulating existing drugs.

Its current lead product candidate is in advanced in Europe and the United States and could hit the market as early as 2019, Mitsubishi Tanabe said.

Explore further: Elan enters $1B royalty deal with Theravance

Related Stories

Elan enters $1B royalty deal with Theravance

May 13, 2013
Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.

Scientific discovery may change treatment of Parkinson's disease

March 22, 2017
When monitoring Parkinson's disease, SPECT imaging of the brain is used for acquiring information on the dopamine activity. A new study conducted in Turku, Finland, shows that the dopamine activity observed in SPECT imaging ...

Horizon Pharma to pay $800M for rare disease drug developer

September 12, 2016
Horizon Pharma will spend about $800 million to buy Raptor Pharmaceutical and expand its portfolio of rare disease treatments, a growing area of focus for drugmakers.

Adamas Pharma rises after IPO raises $48 million

April 10, 2014
Shares of Adamas Pharmaceuticals rose Thursday after the drug developer's initial public offering raised $48 million.

AmerisourceBergen expands into animal health with $2.5B deal

January 12, 2015
Pharmaceutical distributor AmerisourceBergen will stretch its reach into veterinary medicine by spending about $2.5 billion to acquire MWI Veterinary Supply.

Teva buying Auspex for $3.2 billion

March 30, 2015
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Recommended for you

A new therapeutic avenue for Parkinson's disease

January 23, 2018
Systemic clearing of senescent astrocytes prevents Parkinson's neuropathology and associated symptoms in a mouse model of sporadic disease, the type implicated in 95% of human cases. Publishing in Cell Reports, researchers ...

Investigators eye new target for treating movement disorders

January 19, 2018
Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson's disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.

Parkinson's disease 'jerking' side effect detected by algorithm

January 8, 2018
A mathematical algorithm that can reliably detect dyskinesia, the side effect from Parkinson's treatment that causes involuntary jerking movements and muscle spasms, could hold the key to improving treatment and for patients ...

New brainstem changes identified in Parkinson's disease

January 4, 2018
A pioneering study has found that patients with Parkinson's disease have more errors in the mitochondrial DNA within the brainstem, leading to increased cell death in that area.

Caffeine level in blood may help diagnose people with Parkinson's disease

January 3, 2018
Testing the level of caffeine in the blood may provide a simple way to aid the diagnosis of Parkinson's disease, according to a study published in the January 3, 2018, online issue of Neurology, the medical journal of the ...

Researchers shed light on why exercise slows progression of Parkinson's disease

December 22, 2017
While vigorous exercise on a treadmill has been shown to slow the progression of Parkinson's disease in patients, the molecular reasons behind it have remained a mystery.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.